Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With (212)Pb-TCMC-Trastuzumab

PURPOSE: One-year monitoring of patients receiving intraperitoneal (IP) (212)Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS: Eighteen patients with relapsed intra-abdominal human epidermal gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Meredith, Ruby F., Torgue, Julien J., Rozgaja, Tania A., Banaga, Eileen P., Bunch, Patty W., Alvarez, Ronald D., Straughn, J. Michael, Dobelbower, Michael C., Lowy, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Articles: Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449266/
https://www.ncbi.nlm.nih.gov/pubmed/27906723
http://dx.doi.org/10.1097/COC.0000000000000353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449266/
https://www.ncbi.nlm.nih.gov/pubmed/27906723
http://dx.doi.org/10.1097/COC.0000000000000353

Ejemplares similares